Status | Study |
Recruiting |
Study Name: Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Condition: Accelerated Phase Chronic Myelogenous Leukemia Adult Acute Lymphoblastic Leukemia in Remissi Date: 2013-01-02 Interventions: Drug: Fludarabine phosphate Gi |
Completed |
Study Name: MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma Condition: Adult Nasal Type Extranodal NK/T-cell Lymphoma Anaplastic Large Cell Lymphoma Date: 2012-12-11 Interventions: Biological: anti-endosialin/TEM1 monoclonal antibody MORAb-004 |
Active, not recruiting |
Study Name: Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies Condition: Adult Nasal Type Extranodal NK/T-cell Lymphoma Anaplastic Large Cell Lymphoma Date: 2012-08-31 Interventions: Biological: indium In 111 anti-CD45 monoclonal antibody BC8 |
Withdrawn |
Study Name: Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies Condition: Accelerated Phase Chronic Myelogenous Leukemia Acute Myeloid Leukemia With Multilineage Dysp Date: 2012-07-20 Interventions: Drug: cyclophosphamide Given I |
Recruiting |
Study Name: Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Condition: Non-Hodgkin's Lymphoma Hodgkin's Lymphoma Myeloid Leukemia Date: 2012-05-30 Interventions: Drug: Dasatinib Patients recei |
Recruiting |
Study Name: Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Condition: Non-Hodgkin's Lymphoma Multiple Mycosis Fungoides Date: 2012-05-30 Interventions: Drug: Dasatinib Patients receive dasatinib PO every day (QD) for 6 months. |
Active, not recruiting |
Study Name: Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Condition: Accelerated Phase Chronic Myelogenous Leukemia Adult Acute Lymphoblastic Leukemia in Remissi Date: 2012-04-26 Interventions: Biological: tetanus-CMV fusion peptide vaccine |
Active, not recruiting |
Study Name: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Condition: Adult B Acute Lymphoblastic Leukemia Adult T Acute Lymphoblastic Leukemia Date: 2012-03-29 Interventions: Drug: Alisertib Given PO |
Active, not recruiting |
Study Name: Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Condition: Accelerated Phase Chronic Myelogenous Leukemia Adult Acute Lymphoblastic Leukemia in Remissi Date: 2012-02-06 Interventions: Drug: fludarabine phosphate Gi |
Terminated |
Study Name: Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant Condition: Adult Nasal Type Extranodal NK/T-cell Lymphoma Anaplastic Large Cell Lymphoma Date: 2011-08-15 Interventions: Drug: lenalidomide Given PO |